RE: Sweetbiotix?6 Jul 2024 21:18
Coming 10 years now
year end 30 Nov 2014
OptiBiotix’s sugar development screening platform was given a significant boost by the appointment of Dr Sofia Kolida as
director of Research and Development. Dr Kolida has extensive expertise in using novel sugars to modulate the human
microbiome to prevent, manage and treat disease, and their application as food ingredients. We will continue to develop our in house capability at our laboratories at the Science and Technology Centre in Reading.
year end 30 Nov 2015
OptiBiotix’s sugar development platform has progressed rapidly under the leadership of Dr Sofia Kolida. Whilst early development was focused on creating prebiotic sugars with functional properties development programs have been extended to include:
• A new product concept called a SweetBiotix ® , which is a sweet natural healthy sugar not digested in the human gut and
hence calorie free
• A new product concept called an OptiBiotic®, a combination of a targeted probiotic and prebiotic which selectively
enhances the in vivo growth of the probiotic, accentuating its functional properties and health benefits
The SweetBiotix concept is an innovative concept with the potential to address a global requirement, addressing
international concerns over the impact of sugar on obesity, with the prospect of replacing ‘unhealthy’ sugars in existing products with non digestible, low calorie, healthy, SweetBiotix ® . As the food and beverage industry responds to growing public and political concerns over traditional sugars and artificial sweeteners, we expect growing interest in safer, healthy alternatives such as our SweetBiotix® .
The OptiBiotic® concept, is similarly innovative, and directed at companies in the probiotics functional food market who have benefited from the global trend for fortified and functional foods.This market is expected to be worth $46.55bn by 2020
OptiBiotix has contracted the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC) based in Madrid to support the development of these new product concepts. Rapid scientific progress has been rewarded with an early commercial deal with Centro Sperimentale Del Latte (“CSL”), based in Italy, which, develops, manufactures and distributes probiotics, starter cultures, moulds and yeasts for the pharmaceutical, nutraceutical, dairy, food and agricultural sectors all over the world. We believe these innovative product concepts provide significant growth opportunities and will lead to further deals in 2016.
The aim of all these development programmes is to establish a scientific evidence base for mechanism of action, proof of safety and human efficacy, and low cost manufacturability. As products move through the development process risk is reduced and this leads to a corresponding increase in value and greater interest from corporate partners.
just a bit of the early history and possible potential note
Sign In
Follow the stocks
